The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Amgen Inc. lost requests for several judgments in Lindis Biotech GmbH’s patent-infringement lawsuit seeking damages for sales of the leukemia treatment Blincyto, according to a federal judge’s mixed ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Investment analysts at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for shares of Amgen in a ...

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Analysts chewed over early data showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral ...